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Neuraminidase Inhibitors for Treatment
of Influenza A and B Infections
Summary
Influenza epidemics are responsible for an average of approximately
20,000 deaths per year in the United States. The main method for preventing
influenza and its severe complications is influenza vaccination. Influenza-
specific antiviral drugs are an important adjunct to vaccine but are not a
substitute for vaccine. In the United States, four antiviral agents are approved
for preventing or treating influenza: amantadine, rimantadine, zanamivir, and
oseltamivir. Amantadine has been available in the United States since 1976,
and rimantadine has been available since 1993. This report provides
information on two neuraminidase inhibitors, zanamivir and oseltamivir, which
were approved in 1999. Neuraminidase inhibitors are a new class of antiviral
drugs that inhibit influenza A and B viruses. Zanamivir is approved for
treatment of uncomplicated acute illness caused by influenza virus in persons
aged ≥12 years who have been symptomatic for no more than 2 days.
Oseltamivir is approved for treatment of uncomplicated illness caused by
influenza infection in adults aged ≥18 years who have been symptomatic for no
more than 2 days. Neither zanamivir nor oseltamivir is approved for influenza
prophylaxis. This report and the Advisory Committee on Immunization
Practices (ACIP) 1999 recommendations on influenza prevention and control
(MMWR 1999;48[No.RR-4]:1–28) can be accessed at the website for the
Influenza Branch, Division of Viral and Rickettsial Diseases, National Center for
Infectious Diseases, CDC, at <http://www.cdc.gov/ncidod/diseases/flu/
fluvirus.htm> or at the MMWR website at <http://www2.cdc.gov/mmwr/>.
INTRODUCTION
Uncomplicated influenza is characterized by the abrupt onset of constitutional and
respiratory signs and symptoms (e.g., fever, myalgia, headache, severe malaise, nonpro-
ductive cough, sore throat, and rhinitis) (1,2 ). However, in some persons, influenza can
exacerbate underlying medical conditions (e.g., pulmonary or cardiac disease) or lead to
secondary bacterial pneumonia or primary influenza viral pneumonia  (1 ). Epidemics of
influenza occur during the winter months nearly every year and are responsible for an
average of approximately 20,000 deaths per year in the United States (3,4 ). The main
method for preventing influenza and its more severe complications is immunoprophylaxis
with inactivated (i.e., killed-virus) vaccine (1 ). Influenza-specific antiviral drugs for chemo-
prophylaxis or therapy are an important adjunct to vaccine, but they are not a substitute
for influenza vaccine. In the United States, four antiviral agents are approved for prevent-
ing or treating influenza: amantadine hydrochloride and rimantadine hydrochloride as
well as two recently approved neuraminidase inhibitors, zanamivir and oseltamivir.
Amantadine and rimantadine are chemically related antiviral drugs active against in-
fluenza A viruses but not influenza B viruses. After influenza A viruses enter cells, these
drugs inhibit the uncoating of influenza A viruses by blocking the ion-channel activity of
the viral M2  protein (5–10 ). Amantadine was approved in 1976 for treatment and prophy-
laxis of influenza type A infection in adults and children aged ≥1 year. Rimantadine was
approved in 1993 for treatment and prophylaxis of influenza type A infection in adults. For
children, rimantadine was approved only for prophylaxis; however, many experts con-
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sider rimantadine appropriate for treatment of influenza A in children (1 ). (For information
on the use of amantadine and rimantadine, see Recommendations for the Use of Antiviral
Agents for Influenza A in the Advisory Committee on Immunization Practices 1999 recom-
mendations on influenza prevention and control [1 ].)
Zanamivir and oseltamivir, both approved in 1999 by the U.S. Food and Drug Admin-
istration, are members of a new class of antiviral agents that selectively inhibit the
neuraminidase of both influenza A and B viruses. Neuraminidase cleaves terminal sialic
acid residues from carbohydrate moieties on the surfaces of host cells and influenza virus
envelopes; this process promotes the release of progeny viruses from infected cells (11,12 ).
Neuraminidase inhibitors are analogues of sialic acid. Their proposed mechanism of ac-
tion is to block the active site of neuraminidase and leave uncleaved sialic acid residues
on the surfaces of host cells and influenza viral envelopes. Viral hemagglutinin binds to
the uncleaved sialic acid residues; the result is viral aggregation at the host cell surface
and a reduction in the amount of virus that is released and can infect other cells (13 ).
USE OF NEURAMINIDASE INHIBITORS FOR TREATMENT OF
INFLUENZA A AND B INFECTIONS
Laboratory Diagnosis of Influenza
The appropriate treatment of patients with viral respiratory illness depends on accu-
rate and timely diagnosis. The early diagnosis of influenza can help reduce the inappropri-
ate use of antibiotics and provide the option of using antiviral therapy. Influenza surveil-
lance information as well as diagnostic testing (e.g., viral culture and rapid tests for influ-
enza) can aid clinical judgment and help guide treatment decisions.
Influenza surveillance by state and local health departments and CDC can provide
information about the presence of influenza viruses in the community. Surveillance can
also identify the predominant circulating types, subtypes, and strains of influenza.
Several commercial rapid diagnostic tests are available that can be used by laboratories
in outpatient settings to detect influenza viruses within 30 minutes (2 ). Some of these rapid
tests detect only influenza A viruses, whereas other rapid tests detect both influenza A and B
viruses but do not distinguish between the two types. Additional commercial diagnostic
tests are available for use by laboratories performing tests of high complexity (2 ).
Despite the availability of rapid diagnostic tests, the collection of clinical specimens
for viral culture is important because only culture isolates can provide specific informa-
tion on circulating influenza subtypes and strains. This information is needed to compare
current circulating influenza strains and vaccine strains, to guide decisions about influ-
enza treatment and prophylaxis, and to formulate vaccine for the coming year. Virus iso-
lates also are needed to monitor the emergence of antiviral resistance.
Indications for Use of Zanamivir and Oseltamivir
Treatment
Zanamivir is approved for treatment of uncomplicated acute illness caused by influ-
enza virus in adults and adolescents aged ≥12 years who have been symptomatic for no
more than 2 days.* This indication was based on studies in which the predominant influ-
enza infections were influenza A and a limited number of patients with influenza B were
also enrolled (14 ). Zanamivir is not approved for use in children aged <12 years.
* No data are available to support zanamivir’s efficacy if treatment is initiated >48 hours after onset of
illness (14 ).
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Oseltamivir is approved for treatment of uncomplicated acute illness caused by influ-
enza infection in adults aged ≥18 years who have been symptomatic for no more than 2
days.* This indication was based on studies of naturally occurring influenza in which the
predominant infection was influenza A and influenza challenge studies in which the antivi-
ral activity of oseltamivir was supported for influenza A and B (15 ). Oseltamivir is not
approved for use in children (aged <18 years).
When administered within 2 days of illness onset among otherwise healthy adults,
zanamivir and oseltamivir can reduce by approximately 1 day the duration of moderate or
severe symptoms of uncomplicated influenza (16–23 ). The evidence for the efficacy of
both drugs is based primarily on data from patients with fever ≥37.8 C (100 F) at the time
therapy was started.
More clinical data are available concerning the effectiveness of zanamivir and
oseltamivir for treatment of influenza A infection than for treatment of influenza B infec-
tion. However, in vitro data (24–29 ) and data from treatment in mice and ferrets (26,27,30,31 )
document that zanamivir and oseltamivir have activity against influenza B viruses. Lim-
ited data from clinical trials of zanamivir (17,32 ) and from studies of oseltamivir treatment
of experimental influenza B infections (33 ) also suggest that zanamivir and oseltamivir
are  effective for treatment of infections caused by influenza B viruses.
Neither zanamivir nor oseltamivir has been demonstrated to be effective in prevent-
ing serious influenza-related complications, such as bacterial or viral pneumonia or exac-
erbation of chronic diseases. Data are limited and inconclusive concerning the effective-
ness of zanamivir for treatment of influenza in persons at high risk for serious complica-
tions of influenza (17,18,20,34 ). No published data are available concerning the effective-
ness of oseltamivir for treatment of influenza in high-risk populations. No clinical data are
available regarding the safety or efficacy of zanamivir or oseltamivir for pregnant women.
Prophylaxis
Zanamivir and oseltamivir are not approved for prophylactic use. However, recently
published studies of zanamivir and oseltamivir for prophylaxis of influenza in community
settings demonstrated both drugs to be similarly effective in preventing laboratory-con-
firmed clinical influenza with fever (efficacy: zanamivir, 84%; oseltamivir, 82%) (35,36 ).
Experience with prophylactic use of these agents in institutional settings is limited
(37–39 ). Vaccination remains the best prophylaxis for influenza.
Administration of Zanamivir and Oseltamivir
Dosage
The recommended dosage of zanamivir for treatment of influenza in persons aged
≥12 years is two inhalations (one 5-mg blister per inhalation for a total dose of 10 mg)
twice daily (approximately 12 hours apart) for 5 days (14 ).
The recommended dosage of oseltamivir for treatment of influenza in persons aged
≥18 years is 75 mg orally twice daily for 5 days (15 ). A reduction in dosage is recom-
mended for persons with creatinine clearance <30 mL/min (see Persons with Impaired
Renal Function) (15 ).
Route
Zanamivir is available as a dry powder that is self-administered via oral inhalation by
using a plastic device included in the package with the medication. Although the plastic
*No data are available to support oseltamivir’s efficacy if treatment is initiated >40 hours after onset
of illness (15 ) .
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device is similar to devices used to deliver some asthma medications, use of this device
should be restricted to delivery of zanamivir  (40 ). Delivery of the medication requires
loading of a medication disk into the plastic device each day. Patients will benefit from
instruction and demonstration of proper use of the device. Zanamivir is packaged in a disk
with four blisters of medication, each containing a powder mixture of 5 mg of zanamivir
and 20 mg of lactose (14 ).
Oseltamivir is administered orally. It is available as 75-mg capsules (15 ).
Pharmacokinetics
In studies of healthy volunteers, approximately 7%–21% of the orally inhaled zanamivir
dose reached the lungs, and 70%–87% was deposited in the oropharynx (41,42 ). Approxi-
mately 4%–17% of the total amount of orally inhaled zanamivir is systemically absorbed.
Systemically absorbed zanamivir has a half-life of 2.5–5.1 hours and is excreted unchanged
in the urine. Unabsorbed drug is excreted in the feces (14,43 ).
Approximately 80% of orally administered oseltamivir is absorbed systemically (33).
Absorbed oseltamivir is metabolized to GS4071 (oseltamivir carboxylate), the active
neuraminidase inhibitor, primarily by hepatic esterases. GS4071 has a half-life of 6–10
hours and is excreted in the urine by glomerular filtration and tubular secretion via the
anionic pathway (15,44 ). Unmetabolized oseltamivir also is excreted in the urine by glom-
erular filtration and tubular secretion (44 ).
Persons with Impaired Renal Function
Limited data are available regarding the safety and efficacy of zanamivir for patients
with impaired renal function. Among patients with renal failure who were administered a
single intravenous dose of zanamivir in prelicensure studies, decreases in renal clearance
and increases in half-life and systemic exposure to zanamivir were observed (14,45 ). How-
ever, a small number of healthy volunteers who were administered high doses of intrave-
nous zanamivir tolerated systemic levels of zanamivir that were much higher than those
resulting from administration of zanamivir by oral inhalation at the recommended dose
(43,46 ). On the basis of these considerations, the manufacturer recommends no dose
adjustment for inhaled zanamivir for a 5-day course of treatment for patients with either
mild-to-moderate or severe impairment in renal function (45 ).
Among patients with impaired renal function, serum concentrations of oseltamivir
carboxylate increase with declining renal function (15,33 ). A reduction of the dose of
oseltamivir to 75 mg once daily is recommended for patients with creatinine clearance
<30 mL/min (15 ). No data are available concerning the safety or efficacy of oseltamivir in
patients with creatinine clearance <10 mL/min.
Persons with Liver Disease
The pharmacokinetics of zanamivir and oseltamivir have not been studied in patients
with impaired hepatic function (14,15 ).
Side Effects and Adverse Reactions
In clinical treatment studies of inhaled zanamivir, the frequencies of adverse events
were similar for persons receiving inhaled zanamivir and those receiving placebo (i.e.,
inhaled lactose vehicle alone) (14,16–21,47 ). The most common adverse events reported
by both groups were diarrhea; nausea; sinusitis; nasal signs and symptoms; bronchitis;
cough; headache; dizziness; and ear, nose, and throat infections (14,16,17,19,20 ). Each of
these symptoms was reported by <5% of persons in the clinical treatment studies com-
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bined (14 ). Caution is advised if zanamivir is prescribed for patients with underlying chronic
respiratory disease. In a phase I study of persons with mild or moderate asthma who did
not have influenza-like illness, 1 of 13 patients experienced bronchospasm following ad-
ministration of zanamivir (14 ). In addition, preliminary results of a study of zanamivir
treatment of influenza-like illness among persons with asthma or chronic obstructive pul-
monary disease indicated that more patients receiving zanamivir than placebo experi-
enced a >20% decline in forced expiratory volume in 1 second (FEV1) or peak expiratory
flow rates after treatment (14 ). Patients with asthma or chronic obstructive pulmonary
disease are advised to a) have a fast-acting inhaled bronchodilator available when inhal-
ing zanamivir and to b) stop using zanamivir and contact their physician if they develop
difficulty breathing (14 ). Nausea and vomiting were reported more frequently among per-
sons receiving oseltamivir for treatment (nausea without vomiting, approximately 10%;
vomiting, approximately 9%) than among persons receiving placebo (nausea without vom-
iting, approximately 6%; vomiting, approximately 3%) (15,22,23,48 ). However, few per-
sons enrolled in the clinical treatment trials of oseltamivir discontinued treatment because
of these symptoms (15 ). Nausea and vomiting might be less severe if oseltamivir is taken
with food (15,48 ).
Drug Interactions
Although clinical data are limited regarding drug interactions with zanamivir, no known
drug interactions with zanamivir have been reported, and no clinically important drug
interactions have been predicted on the basis of in vitro data and data from studies in rats
(14,49 ). Zanamivir does not affect the cytochrome P450 isoenzymes in human liver mi-
crosomes (14,49 ) and is not expected to alter the metabolism of other drugs metabolized
by these enzymes. Treatment with zanamivir has not been found to impair the immuno-
logic response to influenza vaccine (14,50 ). No published data are available concerning
the safety or efficacy of coadministering amantadine or rimantadine with zanamivir.
Limited clinical data are available regarding drug interactions with oseltamivir. Be-
cause oseltamivir and its active metabolite, GS4071, are excreted in the urine by glomeru-
lar filtration and tubular secretion via the anionic pathway, a potential exists for interac-
tion with other agents excreted by this pathway. For example, coadministration of
oseltamivir and probenecid resulted in a reduction in the clearance of GS4071 by approxi-
mately 50% and a corresponding approximate twofold increase in the plasma levels of
GS4071 (15,44 ). Oseltamivir and GS4071 are not substrates for the cytochrome P450 isoen-
zymes and are not expected to alter the metabolism of other drugs metabolized by these
enzymes (15 ). No published data are available concerning the safety or efficacy of
coadministering amantadine or rimantadine with oseltamivir.
Antiviral Drug Resistance
 Resistance to zanamivir and oseltamivir can be induced in influenza A and B viruses
in vitro (51–58 ), but induction of resistance requires several passages in cell culture. By
contrast, resistance to amantadine and rimantadine in vitro can be induced with fewer
passages in cell culture (10,59 ). Whether these in vitro findings indicate that clinical drug
resistance will occur less frequently with zanamivir and oseltamivir than with amantadine
and rimantadine is unknown. Development of viral resistance to zanamivir and oseltamivir
during treatment has been identified but does not appear to be frequent (15,18,60,61 ).
Currently available diagnostic tests are not optimal for detecting clinical resistance, and
better tests as well as more testing are needed before firm conclusions can be reached.
Postmarketing surveillance for neuraminidase inhibitor-resistant influenza viruses is
planned.
6 MMWR December 17, 1999
Comparison of Current Antiviral Agents
Zanamivir, oseltamivir, amantadine, and rimantadine vary in terms of the types of
influenza viruses they inhibit, route of administration, and approved use in different age
groups (Table 1). No studies have directly compared the effectiveness of these drugs for
treatment of influenza A; however, available information indicates that all four agents are
roughly comparable in reducing the duration of uncomplicated acute illness due to influ-
enza A when treatment is started shortly after onset of symptoms. None of the four agents
has been shown to decrease serious complications of influenza (e.g., pneumonia, hospi-
talization). Information about the use of zanamivir and oseltamivir among persons at high
risk for influenza complications is limited.
The side effects and cost of zanamivir and oseltamivir differ from those of amantadine
and rimantadine. Central nervous system side effects (e.g., nervousness, anxiety, diffi-
culty concentrating, and lightheadedness) have been associated with amantadine and to a
lesser extent with rimantadine (1 ). Amantadine has also been associated with an increased
incidence of seizures among patients with a history of seizure disorders (1 ). Whether
rimantadine is associated with an increased incidence of seizures among patients with a
history of seizure disorders has not been adequately evaluated (1 ). Central nervous sys-
tem side effects have been infrequently reported among patients taking zanamivir and
oseltamivir (14,15 ). Because some persons with underlying asthma or chronic obstruc-
tive pulmonary disease have experienced reduced FEV1 or peak expiratory flow rate fol-
lowing treatment with zanamivir, caution is advised if zanamivir is used by patients with
underlying chronic respiratory disease. Oseltamivir has been associated with nausea and
vomiting. The dose of amantadine, rimantadine, and oseltamivir must be reduced for pa-
tients with renal failure. Finally, zanamivir and oseltamivir are more expensive than
rimantadine, which is more expensive than amantadine (62,63 ).
CONCLUSION
Amantadine has been available since 1976, and rimantadine has been available
since 1993; both drugs have been extensively used for treatment and prophylaxis of
       Amantadine               Rimantadine              Zanamivir                  Oseltamivir
TABLE 1. Comparison of antiviral agents for influenza
Types of influenza Influenza A Influenza A Influenza A and B         Influenza A and B
viruses inhibited
Route of Oral Oral Oral inhalation*          Oral
administration (tablet, capsule, syrup) (tablet, syrup)         (capsule)
Ages for which ≥ 1 year ≥ 14 years ≥ 12 years        ≥ 18 years
treatment is
approved
Ages for which ≥ 1 year ≥ 1 year Not approved          Not approved
prophylaxis is for prophylaxis          for prophylaxis
approved
NOTE: Amantadine manufacturers include Endo Pharmaceuticals (Symetrel® — tablet and syrup);
Invamed and Rosemont (Amantadine HCL — capsule); and Alpharma, Copley Pharmaceutical, HiTech
Pharma, Mikart, Morton Grove, and Pharmaceutical Associates (Amantadine HCL — syrup).
Rimantadine is manufactured by Forest Laboratories (Flumadine® — tablet and syrup). Zanamivir is
manufactured by Glaxo Wellcome (Relenza® — for inhalation). Oseltamivir is manufactured by
Hoffman-La Roche Inc. (Tamiflu® — capsule).
* Zanamivir is administered by using a specially designed plastic oral inhalation device (Diskhaler®).
The device and instructions on its use are included in the package with the medication.
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influenza A. Zanamivir and oseltamivir offer new options for treatment of influenza. Anti-
viral agents for influenza—including amantadine, rimantadine, zanamivir, and oseltamivir—
are an adjunct to vaccine and are not a substitute for vaccine. Immunoprophylaxis with
inactivated (i.e., killed-virus) vaccine remains the principal means for reducing influenza-
related morbidity and death.
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